{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:46:09Z","timestamp":1782452769466,"version":"3.54.5"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital"},{"DOI":"10.13039\/501100009708","name":"NOVO Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF23OC0081717"],"award-info":[{"award-number":["NNF23OC0081717"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The recent Global Consensus supports the use of risankizumab during pregnancy. However, infant clearance following in utero exposure remains unknown, and data on placental transfer are scarce. We report on infant clearance following in utero exposure to risankizumab, and characterize placental transfer and infant outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two pregnant women with inflammatory bowel disease exposed to risankizumab during pregnancy were included. Maternal serum and umbilical cord blood were collected at delivery, and infant serum at 3 and 6\u2009months postpartum. Infant development was assessed using the Ages and Stages Questionnaire\u00ae, and infections and vaccine tolerance were assessed by maternal questionnaire, telephone follow-up, and review of infant medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One woman with ulcerative colitis initiated risankizumab during pregnancy following disease flare, whereas one woman with Crohn\u2019s disease continued intravenous maintenance therapy. Maternal concentrations exceeded cord blood concentrations in both pairs, with a median cord blood-to-maternal ratio of 0.19 (range, 0.14-0.23). At 3\u2009months, the median infant concentration was 0.42\u2009\u03bcg\/mL (range, 0.37-0.47). At 6\u2009months, the concentration was below the lower limit of quantification in one infant (sampling failed in the other). No adverse pregnancy or infant outcomes were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risankizumab showed limited placental transfer, with cord blood concentrations substantially lower than maternal concentrations and clearance within the first 6\u2009months of life. These early findings support the Global Consensus recommendations that risankizumab may be continued during pregnancy and that live BCG vaccine may be administered from 6\u2009months of age, although larger prospective studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag086","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:44:31Z","timestamp":1780487071000},"source":"Crossref","is-referenced-by-count":0,"title":["Limited placental transfer and clearance of risankizumab by 6\u00a0months following\n                    <i>in utero<\/i>\n                    exposure"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8018-5096","authenticated-orcid":false,"given":"Christina","family":"Balmer","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus,","place":["Denmark"]},{"name":"Centre for Preconception and Pregnancy in Autoimmune Diseases [PREG-AID], Department of Clinical Medicine, Aarhus University , Aarhus,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Korgaard","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Henneberg","family":"Holmboe","sequence":"additional","affiliation":[{"name":"Diagnostic Centre, Section of Gastroenterology, Silkeborg Regional Hospital , Silkeborg,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Neldeborg","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3070-8950","authenticated-orcid":false,"given":"Mette","family":"Julsgaard","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus,","place":["Denmark"]},{"name":"Centre for Preconception and Pregnancy in Autoimmune Diseases [PREG-AID], Department of Clinical Medicine, Aarhus University , Aarhus,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026062600535260800_jjag086-B1","doi-asserted-by":"publisher","first-page":"jjaf129","DOI":"10.1093\/ecco-jcc\/jjaf129","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel disease","volume":"19","author":"Mahadevan","year":"2025","journal-title":"J Crohns Colitis."},{"key":"2026062600535260800_jjag086-B2","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1093\/ibd\/izae182","article-title":"Low placental transfer rates of risankizumab among pregnant women with inflammatory bowel disease","volume":"30","author":"Mahadevan","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026062600535260800_jjag086-B3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/ibd\/izaf305","article-title":"Safety of risankizumab during pregnancy in IBD","volume":"32","author":"Tsur","year":"2026","journal-title":"Inflamm Bowel Dis"},{"key":"2026062600535260800_jjag086-B4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000542217","article-title":"Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: Findings from WHO pharmacovigilance study","volume":"186","author":"Jeong","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"2026062600535260800_jjag086-B5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/ueg2.70122","article-title":"International survey of gastroenterologists on managing inflammatory bowel disease during pregnancy and lactation: Current state and the necessity for improvements","volume":"13","author":"Casanova","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"2026062600535260800_jjag086-B6","doi-asserted-by":"publisher","first-page":"ii16","DOI":"10.1093\/ecco-jcc\/jjae048","article-title":"Navigating reproductive care in patients with inflammatory bowel disease: A comprehensive review","volume":"18","author":"Sousa","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026062600535260800_jjag086-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026062600535260800_jjag086-B8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"2026062600535260800_jjag086-B9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cgh.2024.01.008","article-title":"Infant ustekinumab clearance, risk of infection, and development after exposure during pregnancy","volume":"23","author":"Julsgaard","year":"2025","journal-title":"Clin Gastroenterol Hepa\u00adtol"},{"key":"2026062600535260800_jjag086-B10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/apt.16593","article-title":"Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study","volume":"54","author":"Julsgaard","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026062600535260800_jjag086-B11","doi-asserted-by":"publisher","first-page":"e13706","DOI":"10.1111\/cts.13706","article-title":"Risankizumab: Mechanism of action, clinical and translational science","volume":"17","author":"Pang","year":"2024","journal-title":"Clin Transl Sci"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag086\/68624582\/jjag086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/6\/jjag086\/68624582\/jjag086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:53:57Z","timestamp":1782449637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag086\/8718666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag086","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"jjag086"}}